OBJECTIVES: Identification of tumor-specific somatic mutations has had a significant impact on both disease diagnosis and therapy selection. The ability of next-generation sequencing (NGS) to provide a quantitative assessment of mutant allele burden, in numerous target genes in a single assay, provides a significant advantage over conventional qualitative genotyping platforms. METHODS: We assessed the quantitative capability of NGS and a primer extension-based matrix-assisted laser desorption ionization-time-of-flight (PE-MALDI) assay and directly correlated NGS mutant allele burden determination to morphologic assessment of tumor percentage in H&E-stained slides. RESULTS: Our results show a 100% concordance between NGS and PE-MALDI in mutant allele detection and a significant correlation between NGS and PE-MALDI for determining mutant allele burden when mutant allele burden is 10% or more. CONCLUSIONS: NGS-based mutation screening provides a quantitative assessment comparable to that of PE-MALDI. In addition, NGS also allows for a high degree of multiplexing and uses nanogram quantities of DNA, thereby preserving precious material for future analysis. Furthermore, this study provides evidence that H&E-based morphologic assessment of tumor burden does not correlate to actual tumor mutant allele burden frequency.
OBJECTIVES: Identification of tumor-specific somatic mutations has had a significant impact on both disease diagnosis and therapy selection. The ability of next-generation sequencing (NGS) to provide a quantitative assessment of mutant allele burden, in numerous target genes in a single assay, provides a significant advantage over conventional qualitative genotyping platforms. METHODS: We assessed the quantitative capability of NGS and a primer extension-based matrix-assisted laser desorption ionization-time-of-flight (PE-MALDI) assay and directly correlated NGS mutant allele burden determination to morphologic assessment of tumor percentage in H&E-stained slides. RESULTS: Our results show a 100% concordance between NGS and PE-MALDI in mutant allele detection and a significant correlation between NGS and PE-MALDI for determining mutant allele burden when mutant allele burden is 10% or more. CONCLUSIONS: NGS-based mutation screening provides a quantitative assessment comparable to that of PE-MALDI. In addition, NGS also allows for a high degree of multiplexing and uses nanogram quantities of DNA, thereby preserving precious material for future analysis. Furthermore, this study provides evidence that H&E-based morphologic assessment of tumor burden does not correlate to actual tumor mutant allele burden frequency.
Entities:
Keywords:
AmpliSeq Cancer Panel; Ion Torrent; Massarray; Mutant allele burden; Mutant allele frequency; Next-generation sequencing; Sequenom
Authors: Elena M Stoffel; Rune Erichsen; Trine Frøslev; Lars Pedersen; Mogens Vyberg; Erika Koeppe; Seth D Crockett; Stanley R Hamilton; Henrik T Sørensen; John A Baron Journal: Gastroenterology Date: 2016-07-19 Impact factor: 22.682
Authors: Wendy W J de Leng; Christa G Gadellaa-van Hooijdonk; Françoise A S Barendregt-Smouter; Marco J Koudijs; Ies Nijman; John W J Hinrichs; Edwin Cuppen; Stef van Lieshout; Robert D Loberg; Maja de Jonge; Emile E Voest; Roel A de Weger; Neeltje Steeghs; Marlies H G Langenberg; Stefan Sleijfer; Stefan M Willems; Martijn P Lolkema Journal: PLoS One Date: 2016-02-26 Impact factor: 3.240
Authors: Rick Kamps; Rita D Brandão; Bianca J van den Bosch; Aimee D C Paulussen; Sofia Xanthoulea; Marinus J Blok; Andrea Romano Journal: Int J Mol Sci Date: 2017-01-31 Impact factor: 5.923
Authors: Yoonjung Kim; Chi Heum Cho; Jung Sook Ha; Do Hoon Kim; Sun Young Kwon; Seoung Chul Oh; Kyung A Lee Journal: J Gynecol Oncol Date: 2019-08-06 Impact factor: 4.401